Posted by Michael Wonder on 06 Oct 2021
Johnson & Johnson announces submission of emergency use authorisation amendment to the U.S. FDA to support booster of its single shot COVID-19 vaccine
5 October 2021 - Submission includes data showing a booster increased protection to 94% against moderate to severe/critical COVID-19 in the U.S..
Johnson & Johnson announced it has submitted data to the U.S. FDA to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age and older.
